THE INFLUENCE OF CYP2C8*3 ON CARBAMAZEPINE SERUM
CONCENTRATION IN EPILEPTIC PEDIATRIC PATIENTS
Milovanovic DD, Milovanovic JR, Radovanovic M, Radosavljevic I,
Obradovic S, Jankovic S, Milovanovic D, Djordjevic N
*Corresponding Author: M.D., Ph.D., Associate Professor, Department of Pharmacology
and Toxicology, Faculty of Medical Sciences, University of Kragujevac, Svetozara Markovica 69, 34 000 Kragujevac,
Serbia. Tel: +381-34-306-800, ext 223. Fax: +381-34-306-800. E-mail: natashadj2002@yahoo.com
page: 21
|
|
REFERENCES
1. Brunton LL, Lazo JS, Parker KL, Eds. Goodman
and Gilman’s The Pharmacological Basis
of Therapeutics, 11th ed. New York, NY, USA:
The McGraw-Hill Companies Inc., 2006.
2. Ritter JM, Lewis LD, Mant TG, Ferro A, Eds. A
Textbook of Clinical Pharmacology and Therapeutics,
5th ed. London, UK: Hodder Arnold, an
imprint of Hodden Education, part of Hachette
Livre UK, 2008.
3. Wells BG, Dipiro JT, Schwinghammer TL, Dipiro
CV, Eds. Pharmacotherapy Handbook, 7th ed.
New York, NY, USA: The McGraw-Hill Companies,
Inc., 2009.
4. Tomalik-Scharte D, Fuhr U, Hellmich M, Frank
D, Doroshyenko O, et al. Effect of the CYP2C8
genotype on the pharmacokinetics and pharmacodynamics
of repaglinide. Drug Metab Disposition.
2011; 39(5): 927-932.
5. Pechandova K, Buzkova H, Matouskova O,
Perlik F, Slanar O. Genetic polymorphisms of
CYP2C8 in the Czech Republic. Genet Test Mol
Biomarkers. 2012; 16(7): 812-816.
6. Aquilante CL, Bushman LR, Knutsen SD, Burt
LE, Rome LC, Kosmiski LA. Influence of SLCO1B1
and CYP2C8 gene polymorphisms on
rosiglitazone pharmacokinetics in healthy volunteers.
Hum Genomics. 2008; 3(1): 7-16.
7. Yokoi T. Essentials for starting a pediatric clinical
study (1): Pharmacokinetics in children. J
Toxicol Sci. 2009; 34(2): 307-312.
8. Cella M, Knibbe C, Danhof M, Pasqua OD. What
is the right dose for children. Br J Clin Pharmacol.
2010; 70(4): 597-603.
9. Djordjevic N, Milovanovic DD, Radovanovic
M, Radosavljevic I, Obradovic S, Jakovljevic M, et al. CYP1 A2 genotype affects carbamazepine
pharmacokinetics in children with epilepsy. Eur
J Clin Pharmacol. 2016; 72(4): 439-445.
10. Jankovic SM, Jovanovic D, Milovanovic JR.
Phar-macokinetic modeling of carbamazepine
based on clinical data from Serbian epileptic
patients. Methods Find Exp Clin Pharmacol.
2008; 30(9): 707-713.
11. Nakajima M, Fujiki Y, Noda K, Ohtsuka H, Ohkuni
H, Kyo S, et al. Genetic polymorphism of
CYP2 C8 in Japaneze population. Drug Metab
Dispos. 2003; 31(6): 687-690.
12. Aquilante CL, Niemi M, Gong L, Altman RB,
Klein TE. PharmGKB summary: Very important
pharma-cogene information for cytochrome
P450, family 2, subfamily C, polypeptide 8. Pharmacogenet
Genomics. 2013; 23(12): 721-728.
13. Hichiya H, Tanaka-Kagawa T, Soyama A, Jinno
H, Koyano S, Katori N, et al. Functional characterization
of five novel CYP2C8 variants,
G171S, R186X, R186G, K247R, and K383N,
found in a Japanese population. Drug Metab
Dispos. 2005; 33(5): 630-636.
14. Whirl-Carrillo M, McDonagh EM, Hebert JM,
Gong L, Sangkuhl K, Thorn CF, et al. Pharmacogenomics
knowledge for personalized medicine.
Clin Pharmacol Ther. 2012; 92(4): 414-417.
15. Ferguson SS, Chen Y, LeCluyse EL, Negishi M,
Goldstein JA. Human CYP2C8 is transcriptionally
regulated by the nuclear receptors constitutive
androstane receptor, pregnane X receptor, glucocorticoid
receptor, and hepatic nuclear factor
4alpha. Mol Pharmacol. 2005; 68(3): 747-757.
16. Oscarson M, Zanger UM, Rifki OF, Klein K,
Eichelbaum M, Meyer UA. Transcriptional profiling
of genes induced in the livers of patients
treated with car-bamazepine. Clin Pharmacol
Ther. 2006; 80(5): 440-456.
17. Owen A, Goldring C, Morgan P, Park BK, Pirmohamed
M. Induction of P-glycoprotein in lymphocytes
by carbamazepine and rifampicin: The
role of nuclear hormone response elements. Br
J Clin Pharmacol. 2006; 62(2): 237-242.
18. Thorn CF, Leckband SG, Kelsoe J, Leeder JS,
Muller DJ, Klein TE, et al. PharmGKB summary:
Car-bamazepine pathway. Pharmacogenet
Genomics. 2011; 21(12): 906-910.
19. Soyama A, Saito Y, Momamura K, Ueno K,
Kamakura S, Ozawa S, et al. Five novel single
nucleotide polymorphisms in the CYP2C8 gene,
one of which induces a frame-shift. Drug Metabol
Pharmacokin. 2002; 17(4): 374-377.
20. Bahadur N, Leathart JB, Mutch E, Steimel-Crespi
D, Dunn SA, Gilissen R, et al. CYP2C8 polymorphisms
in Caucasians and their relationship
with paclitaxel 6alpha-hydroxylase activity in
human liver microsomes. Biochem Pharmacol.
2002; 64(11): 1579-1589.
21. Niemi M, Leathart JB, Neuvonen M, Backman
JT, Daly AK, Neuvonen PJ. Polymorphism in
CYP2C8 is associated with reduced plasma concentrations
of repaglinide. Clin Pharmacol Ther.
2003; 74(4): 380-387.
22. Martínez C, García-Martín E, Blanco G, Gamito
FJG, Ladero JM, Agúndez JAG. The effect of
the cytochrome P450 CYP2C8 polymorphism
on the disposition of (R)-ibuprofen enantiomer
in healthy subjects. Br J Clin Pharmacol. 2004;
59(1): 62-68.
23. Kirchheiner J, Thomas S, Bauer S, Tomalik-
Scharte D, Hering U, Doroshyenko O, et al.
Pharmacokinetics and pharmacodynamics of
rosiglitazone in relation to CYP2C8 genotype.
Clin Pharmacol Ther. 2006; 80(6): 657-667.
24. Bergmann TK, Brasch-Andersen C, Green H,
Mirza M, Pedersen RS, Nielsen F, et al. Impact
of CYP2 C8 *3 on paclitaxel clearance: A population
pharmacokinetic and pharmacogenomic
study in 93 patients with ovarian cancer. Pharmacogenomics
J. 2011; 11(2): 113-120.
25. Wójcikowski J, Basińska A, Daniel WA. The
cytochrome P450-catalyzed metabolism of levomepromazine:
A phenothiazine neuroleptic
with a wide spectrum of clinical application.
Biochem Pharmacol. 2014; 90(2): 188-195.
26. Daily EB, Aquilante CL. Cytochrome P450 2C8
pharmacogenetics: A review of clinical studies.
Pharmacogenomics. 2009; 10(9): 1489-1510.
27. Kaspera R, Naraharisetti SB, Evangelista EA,
Marciante KD, Psaty BM, Totah RA. Drug metabolism
by CYP2C8.3 is determined by substrate
dependent interactions with cytochrome
P450 reductase and cytochrome b5. Biochem
Pharmacol. 2011; 82(6): 681-691.
28. Liu H, Delgado MR. Influence of sex, age,
weight, and carbamazepine dose on serum concentrations,
concentration ratios, and level/dose
ratios of carbamazepine and its metabolites. Ther
Drug Monit. 1994; 16(5): 469-476.
29. Gray AL, Botha JH, Miller R. A model for the
determination of carbamazepine clearance in
children on mono- and polytherapy. Eur J Clin
Pharmacol. 1998; 54(4): 359-362.
30. Chan E, Lee HS, Hue SS. Population pharmacokinetics
of carbamazepine in Singapore epileptic
patients. Br J Clin Pharmacol. 2001; 51(6): 567-576
31. Deleu D, Aarons L, Ahmed I. Population pharmacokinetics
of free carbamazepine in adult
Omani epileptic patients. Eur J Clin Pharmacol.
2001; 57(3): 243-248.
32. Jiao Z, Shi XJ, Zhao ZG, Zhong MK. Population
pharmacokinetic modeling of steady state
clearance of carbamazepine and its epoxide metabolite
from sparse routine clinical data. J Clin
Pharm Ther. 2004; 29(3): 247-256.
33. Furlanut M, Montanari G, Bonin P, Casara GL.
Carbamazepine and carbamazepine-10,11-epoxide
serum concentrations in epileptic children. J
Pediatr. 1985; 106(3): 491-495.
34. Summers B, Summers RS. Carbamazepine clearance
in pedetric epilepsy patients. Influence of
both mass, dose, sex and co-medication. Clin
Pharmacokin. 1989; 17(3): 208-216.
35. Reith DM, Hooper WD, Parke J, Charles B.
Population pharmacokinetic modeling of steady
state carbamazepine clearance in children, adolescents,
and adults. J Pharmacokinet Pharmacodyn.
2001; 28(1): 79-92.
36. El Desoky ES, Sabarinath SN, Hamdi MM,
Bewernitz M, Derendorf H. Population pharmacokinetics
of steady-state carbamazepine in
Egyptian epilepsy patients. J Clin Pharm Ther.
2012; 37(3): 352-355.
37. Wang Y, Zhang HN, Niu CH, Gao P, Chen YJ,
Peng J, et al. Population pharmacokinetics modeling
of oxcarbazepine to characterize drug interactions
in Chinese children with epilepsy. Acta
Pharmacol Sin. 2014; 35(10): 1342-1350.
38. Milovanovic JR, Jankovic SM. Factors influencing
carbamazepine pharmacokinetics in children
and adults: Population pharmacokinetic analysis.
Int J Clin Pharmacol Ther. 2011; 49(7): 428-436.
39. Delgado Iribarnegaray MF, Santo Bueldga D,
García Sánchez MJ, Otero MJ, Falcão AC,
Domínguez-Gil A. Carbamazepine population
pharmacokinetics in children: Mixed-effect
models. Ther Drug Monit. 1997; 19(2): 132-139.
40. Jiao Z, Zhong MK, Shi XJ, Hu M, Zhang JH.
Population pharmacokinetics of carbamazepine
in Chinese epilepsy patients. Ther Drug Monit.
2003;25(3):279-286.
|
|
|
|
 |
Number 27
VOL. 27 (2), 2024 |
Number 27
VOL. 27 (1), 2024 |
Number 26
Number 26 VOL. 26(2), 2023 All in one |
Number 26
VOL. 26(2), 2023 |
Number 26
VOL. 26, 2023 Supplement |
Number 26
VOL. 26(1), 2023 |
Number 25
VOL. 25(2), 2022 |
Number 25
VOL. 25 (1), 2022 |
Number 24
VOL. 24(2), 2021 |
Number 24
VOL. 24(1), 2021 |
Number 23
VOL. 23(2), 2020 |
Number 22
VOL. 22(2), 2019 |
Number 22
VOL. 22(1), 2019 |
Number 22
VOL. 22, 2019 Supplement |
Number 21
VOL. 21(2), 2018 |
Number 21
VOL. 21 (1), 2018 |
Number 21
VOL. 21, 2018 Supplement |
Number 20
VOL. 20 (2), 2017 |
Number 20
VOL. 20 (1), 2017 |
Number 19
VOL. 19 (2), 2016 |
Number 19
VOL. 19 (1), 2016 |
Number 18
VOL. 18 (2), 2015 |
Number 18
VOL. 18 (1), 2015 |
Number 17
VOL. 17 (2), 2014 |
Number 17
VOL. 17 (1), 2014 |
Number 16
VOL. 16 (2), 2013 |
Number 16
VOL. 16 (1), 2013 |
Number 15
VOL. 15 (2), 2012 |
Number 15
VOL. 15, 2012 Supplement |
Number 15
Vol. 15 (1), 2012 |
Number 14
14 - Vol. 14 (2), 2011 |
Number 14
The 9th Balkan Congress of Medical Genetics |
Number 14
14 - Vol. 14 (1), 2011 |
Number 13
Vol. 13 (2), 2010 |
Number 13
Vol.13 (1), 2010 |
Number 12
Vol.12 (2), 2009 |
Number 12
Vol.12 (1), 2009 |
Number 11
Vol.11 (2),2008 |
Number 11
Vol.11 (1),2008 |
Number 10
Vol.10 (2), 2007 |
Number 10
10 (1),2007 |
Number 9
1&2, 2006 |
Number 9
3&4, 2006 |
Number 8
1&2, 2005 |
Number 8
3&4, 2004 |
Number 7
1&2, 2004 |
Number 6
3&4, 2003 |
Number 6
1&2, 2003 |
Number 5
3&4, 2002 |
Number 5
1&2, 2002 |
Number 4
Vol.3 (4), 2000 |
Number 4
Vol.2 (4), 1999 |
Number 4
Vol.1 (4), 1998 |
Number 4
3&4, 2001 |
Number 4
1&2, 2001 |
Number 3
Vol.3 (3), 2000 |
Number 3
Vol.2 (3), 1999 |
Number 3
Vol.1 (3), 1998 |
Number 2
Vol.3(2), 2000 |
Number 2
Vol.1 (2), 1998 |
Number 2
Vol.2 (2), 1999 |
Number 1
Vol.3 (1), 2000 |
Number 1
Vol.2 (1), 1999 |
Number 1
Vol.1 (1), 1998 |
|
|
